BALPHARMAPharmaceuticals
Bal Pharma Ltd — Profit & Loss Statement
₹60.42
-1.51%
Bal Pharma Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | 0.03 Cr | 0.65 Cr | — |
| Tax Rate For Calcs | 0.30 | 0.18 | 0.24 | 0.29 | — |
| Normalized EBITDA | 31.76 Cr | 33.60 Cr | 24.24 Cr | 24.85 Cr | — |
| Total Unusual Items | 0.00 | 0.00 | 0.13 Cr | 2.24 Cr | — |
| Total Unusual Items Excluding Goodwill | 0.00 | 0.00 | 0.13 Cr | 2.24 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 7.22 Cr | 7.39 Cr | 2.57 Cr | 5.61 Cr | — |
| Reconciled Depreciation | 9.77 Cr | 10.07 Cr | 9.13 Cr | 9.04 Cr | — |
| Reconciled Cost Of Revenue | 157.89 Cr | 191.75 Cr | 176.24 Cr | 167.82 Cr | — |
| EBITDA | 31.76 Cr | 33.60 Cr | 24.37 Cr | 27.10 Cr | — |
| EBIT | 21.99 Cr | 23.53 Cr | 15.24 Cr | 18.06 Cr | — |
| Net Interest Income | -16.85 Cr | -14.48 Cr | -12.08 Cr | -10.54 Cr | — |
| Interest Expense | 16.85 Cr | 14.48 Cr | 10.50 Cr | 8.88 Cr | — |
| Normalized Income | 7.22 Cr | 7.39 Cr | 2.47 Cr | 4.02 Cr | — |
| Net Income From Continuing And Discontinued Operation | 7.22 Cr | 7.39 Cr | 2.57 Cr | 5.61 Cr | — |
| Total Expenses | 283.29 Cr | 318.54 Cr | 284.16 Cr | 264.64 Cr | — |
| Diluted Average Shares | 1.58 Cr | 1.50 Cr | 1.57 Cr | 1.48 Cr | — |
| Basic Average Shares | 1.58 Cr | 1.50 Cr | 1.57 Cr | 1.48 Cr | — |
| Diluted EPS | 4.56 | 4.94 | 1.67 | 3.79 | — |
| Basic EPS | 4.56 | 4.94 | 1.67 | 3.79 | — |
| Diluted NI Availto Com Stockholders | 7.22 Cr | 7.39 Cr | 2.57 Cr | 5.61 Cr | — |
| Net Income Common Stockholders | 7.22 Cr | 7.39 Cr | 2.57 Cr | 5.61 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 7.22 Cr | 7.39 Cr | 2.57 Cr | 5.61 Cr | — |
| Minority Interests | -0.02 Cr | -0.05 Cr | -0.05 Cr | -0.09 Cr | — |
| Net Income Including Noncontrolling Interests | 7.24 Cr | 7.45 Cr | 2.62 Cr | 5.70 Cr | — |
| Net Income Continuous Operations | 7.24 Cr | 7.45 Cr | 2.62 Cr | 5.70 Cr | — |
| Tax Provision | -2.10 Cr | 1.60 Cr | 2.13 Cr | 3.48 Cr | — |
| Pretax Income | 5.14 Cr | 9.05 Cr | 4.75 Cr | 9.18 Cr | — |
| Other Non Operating Income Expenses | 2.20 Cr | 2.85 Cr | 0.58 Cr | 1.73 Cr | — |
| Special Income Charges | 0.00 | 0.00 | 0.13 Cr | 2.24 Cr | — |
| Net Non Operating Interest Income Expense | -16.85 Cr | -14.48 Cr | -12.08 Cr | -10.54 Cr | — |
| Interest Expense Non Operating | 16.85 Cr | 14.48 Cr | 10.50 Cr | 8.88 Cr | — |
| Operating Income | 19.79 Cr | 20.68 Cr | 17.55 Cr | 15.06 Cr | — |
| Operating Expense | 125.40 Cr | 126.79 Cr | 107.92 Cr | 96.82 Cr | — |
| Other Operating Expenses | 53.23 Cr | 56.24 Cr | 26.59 Cr | 23.05 Cr | — |
| Depreciation And Amortization In Income Statement | 9.77 Cr | 10.07 Cr | 9.13 Cr | 9.04 Cr | — |
| Depreciation Income Statement | 9.77 Cr | 10.07 Cr | 7.16 Cr | 7.57 Cr | — |
| Gross Profit | 145.19 Cr | 147.47 Cr | 125.46 Cr | 111.88 Cr | — |
| Cost Of Revenue | 157.89 Cr | 191.75 Cr | 176.24 Cr | 167.82 Cr | — |
| Total Revenue | 303.08 Cr | 339.22 Cr | 301.71 Cr | 279.70 Cr | — |
| Operating Revenue | 303.08 Cr | 339.22 Cr | 301.71 Cr | 279.70 Cr | — |
| Interest Income | — | 0.56 Cr | 0.23 Cr | 0.37 Cr | 0.31 Cr |
| Rent Expense Supplemental | — | 1.05 Cr | 0.76 Cr | 0.56 Cr | 0.68 Cr |
| Other Special Charges | — | -0.08 Cr | -0.13 Cr | -2.24 Cr | 0.05 Cr |
| Total Other Finance Cost | — | 2.54 Cr | 1.82 Cr | 2.03 Cr | 1.62 Cr |
| Interest Income Non Operating | — | 0.56 Cr | 0.23 Cr | 0.37 Cr | 0.31 Cr |
| Amortization | — | 3.92 Cr | 1.97 Cr | 1.47 Cr | 1.19 Cr |
| Selling General And Administration | — | 22.17 Cr | 18.20 Cr | 17.52 Cr | 12.39 Cr |
| Selling And Marketing Expense | — | 17.90 Cr | 14.77 Cr | 14.82 Cr | 10.27 Cr |
| General And Administrative Expense | — | 4.27 Cr | 3.42 Cr | 2.71 Cr | 2.13 Cr |
| Rent And Landing Fees | — | 1.05 Cr | 0.76 Cr | 0.56 Cr | 0.68 Cr |
| Write Off | — | — | 0.00 | 0.00 | 0.00 |
| Research And Development | — | — | 0.00 | 0.00 | 0.02 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Bal Pharma Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.